Sihuan Pharma Acquires Beijing Combio, an Antibody/Bispecific Company

Sihuan Pharma will acquire Beijing Combio Pharma for an undisclosed price. An innovative biopharma, Combio is developing 12 preclinical molecules that it discovered using its two antibody platforms: Mab Edit (antibody editing) and Mebs-Ig (antibody editing for bispecific antibodies). Combio will become part of Sihuan's existing novel drug development company, Xuanzhu Biopharm. In August 2020, Xuanzhu raised $148 million in venture capital at a $700 million valuation. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: // //